At ClexBio, we envision a world where no patient needs to die while waiting for an organ transplant, and where organ models can help to predict the effect of pharmaceuticals faster and more accurately to get them in the hands of suffering patients faster.
The foundation of ClexBio is our fully-owned, proprietary hydrogel technology CLEX, is the result of more than 7 years of R&D within tissue engineering at NTNU, Harvard University, EPFL, and the University of Birmingham and has been published in internationally recognized scientific journals. CLEX was designed to overcome key challenges in biofabrication and deposit living cells in close proximity on the micro-scale. By combining advanced biofabrication tools, biomaterials, and living human cells, we aim to solve the biggest bottleneck in organ engineering – recreating vasculature. Our goal is to be the first company to engineer patient-specific blood vessels for preclinical and clinical applications.
We are two co-founders with academic & industrial expertise from leading universities and biotechs globally and are supported by a world-class team of A-level entrepreneurs and innovators to help us realize our mission. Since we started in January 2020, we have raised significant seed funding and are rapidly growing our team.
If you’d like to be a part of the journey, get in touch with us today.
The foundation of ClexBio is our fully-owned, proprietary hydrogel technology CLEX, is the result of more than 7 years of R&D within tissue engineering at NTNU, Harvard University, EPFL, and the University of Birmingham and has been published in internationally recognized scientific journals. CLEX was designed to overcome key challenges in biofabrication and deposit living cells in close proximity on the micro-scale. By combining advanced biofabrication tools, biomaterials, and living human cells, we aim to solve the biggest bottleneck in organ engineering – recreating vasculature. Our goal is to be the first company to engineer patient-specific blood vessels for preclinical and clinical applications.
We are two co-founders with academic & industrial expertise from leading universities and biotechs globally and are supported by a world-class team of A-level entrepreneurs and innovators to help us realize our mission. Since we started in January 2020, we have raised significant seed funding and are rapidly growing our team.
If you’d like to be a part of the journey, get in touch with us today.
Location: Norway, Oslo
Employees: 1-10
Total raised: $2.2M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 24.05.2022 | Iaso Ventu... | iasoventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.07.2021 | - | $2.2M | - |
Mentions in press and media 3
| Date | Title | Description |
| 22.04.2026 | DARE Campus opens deep tech hub in Schlieren | DARE Campus, a new deep tech office and lab space at The JED in Schlieren operated by flexoffice, has opened its doors. The space located at the new building D of the JED Campus covers around 3,000 m² and is able to accommodate up to 20 co... |
| 21.07.2021 | ClexBio Raises USD 2.2M in Financing | ClexBio, a Oslo, Norway-based startup developing bioengineered human blood vessels for transplant, secured US$2.2m in seed funding. The financing included US$1.2m from angel investors across Europe and Asia, including board members of Globa... |
| 20.07.2021 | ClexBio : Oversubscribes Financing Round Totalling USD 2.2M to Develop Engineered Human Blood Vessel Transplants | ClexBio, a start-up developing bioengineered human blood vessels for transplant, has secured US$2.2m in seed funding from private investors and governmental grants. “The broad backing we have received from international A-level angel invest... |